TOP TEN perturbations for 1553529_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553529_at
Selected probe(set): 1553529_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553529_at (1553529_at) across 6672 perturbations tested by GENEVESTIGATOR:

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.89251995
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.7948446
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.79449844
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.77316856
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

inclusion body myositis study 2 / normal quadriceps tissue

Relative Expression (log2-ratio):-0.74619293
Number of Samples:5 / 2
Experimental inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal quadriceps tissue
Quadriceps femoris biopsy muscle samples from control subjects.

Becker muscular dystrophy study 3 (biceps brachii) / normal skeletal muscle tissue (adult)

Relative Expression (log2-ratio):-0.73519325
Number of Samples:3 / 6
Experimental Becker muscular dystrophy study 3 (biceps brachii)
Biceps brachii biopsies obtained from patients with Becker muscular dystrophy (BMD).
Control normal skeletal muscle tissue (adult)
Commercially purchased normal adult skeletal muscle tissue samples.

HCC study 27 (young; validation) / HCC study 27 (elder; validation)

Relative Expression (log2-ratio):-0.7262964
Number of Samples:21 / 10
Experimental HCC study 27 (young; validation)
Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a validation cohort.
Control HCC study 27 (elder; validation)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort.

diclofenac study 7 (24h) / vehicle (PBS) treated HepG2 cell sample

Relative Expression (log2-ratio):0.6944027
Number of Samples:3 / 3
Experimental diclofenac study 7 (24h)
HepG2 cells exposed to 100μM diclofenac in PBS solvent for 24 hours. ATC code:, ,
Control vehicle (PBS) treated HepG2 cell sample
HepG2 cells exposed to 0.5% PBS solvent for 24 hours.

HCC study 27 (elder; validation) / HCC study 27 (elder; training)

Relative Expression (log2-ratio):0.66745853
Number of Samples:10 / 32
Experimental HCC study 27 (elder; validation)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort.
Control HCC study 27 (elder; training)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a training cohort.

rheumatoid arthritis study 31 / IFNa-2a study 1

Relative Expression (log2-ratio):-0.6516342
Number of Samples:4 / 7
Experimental rheumatoid arthritis study 31
Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocytes from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA.
Control IFNa-2a study 1
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml IFNα2a in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and they were sorted from remaining peripheral blood leukocytes by CD14 labeling.